Macitentan

Known as: Macitentanum, N-(5-(4-Bromophenyl)-6-(2-((5-Bromopyrimidin-2-Yl)Oxi)Ethoxy)Pyrimidin-4-Yl)-N'-Propylsulfuric Diamide, N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
0204020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVES This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary… (More)
Is this relevant?
2015
2015
PURPOSE The objective of the study was to determine whether astrocytes and brain endothelial cells protect glioma cells from… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2012
2012
Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel… (More)
Is this relevant?
2012
2012
Macitentan is a tissue-targeting, dual endothelin receptor antagonist, currently under phase 3 investigation in pulmonary… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2011
2011
To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2010
2010
Macitentan (ACT-064992), under development by Actelion Ltd in collaboration with Japanese licensee Nippon Shinyaku Co Ltd, is an… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?